Stay updated on market trends for XLO. Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? AbbVie and Xilio partner to develop tumor-activated immunotherapies.

Short interest in Xilio Therapeutics Inc (NASDAQ:XLO) increased during the last reporting period, rising from 575.45K to 644.54K. This put 1.46% of the company's publicly available shares short.